---
title: "BTIG Reaffirms Their Buy Rating on I-MAB (IMAB)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/262619711.md"
description: "According to TipRanks, Zelin is a 4-star analyst with an average return of 5.9% and a 36.51% success rate. Zelin covers the Healthcare sector, focusing on stocks such as I-MAB, Viking Therapeutics, and Verastem. I-MAB has an analyst consensus of Strong Buy, with a price target consensus of $7.80."
datetime: "2025-10-24T11:45:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/262619711.md)
  - [en](https://longbridge.com/en/news/262619711.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/262619711.md)
---

# BTIG Reaffirms Their Buy Rating on I-MAB (IMAB)

According to TipRanks, Zelin is a 4-star analyst with an average return of 5.9% and a 36.51% success rate. Zelin covers the Healthcare sector, focusing on stocks such as I-MAB, Viking Therapeutics, and Verastem.

I-MAB has an analyst consensus of Strong Buy, with a price target consensus of $7.80.

### Related Stocks

- [IMAB.US](https://longbridge.com/en/quote/IMAB.US.md)
- [NBP.US](https://longbridge.com/en/quote/NBP.US.md)

## Related News & Research

- [3 Financially Strong Penny Stocks Worth A Closer Look](https://longbridge.com/en/news/295400050.md)
- [Regulatory and Data Risks Loom Over Immix Biopharma’s Clinical Programs and Valuation](https://longbridge.com/en/news/295383459.md)
- [Protagonist Therapeutics (PTGX) Swings To Net Income, Is The Valuation Too Expensive?](https://longbridge.com/en/news/295354544.md)
- [Immunocore Holdings (IMCR) Posted Strong Earnings, Is The 49% Undervaluation Case Convincing?](https://longbridge.com/en/news/295336766.md)
- [Is Iovance Biotherapeutics (IOVA) Undervalued On Q2 Earnings And Reaffirmed Guidance?](https://longbridge.com/en/news/295324260.md)